Menu Search
Equities

Shionogi & Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
SH0:STU

Shionogi & Co Ltd

Actions
  • Price (EUR)15.00
  • Today's Change0.300 / 2.04%
  • Shares traded0.00
  • 1 Year change+27.12%
  • Beta0.6088
Data delayed at least 15 minutes, as of Jun 30 2025.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shionogi & Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company is mainly engaged in the research and development, purchasing, manufacturing, sales, and related activities of ethical pharmaceuticals. The Company is engaged in research and development, purchasing, manufacturing, and marketing of pharmaceuticals for the treatment of gram-negative bacterial infections, influenza virus infections, new coronavirus infections, invasive aspergillus infections, complicated urinary tract infections including pyelonephritis, Alzheimer's disease, chronic pain, cancer of the esophagus, bladder, head and neck, solid tumors, and other diseases. The Company provides products and services in Japan, Europe, North America, and other regions.

  • Revenue in JPY (TTM)438.27bn
  • Net income in JPY170.44bn
  • Incorporated1919
  • Employees4.96k
  • Location
    Shionogi & Co Ltd3-1-8, Dosho-machi, Chuo-kuOSAKA-SHI 541-0045JapanJPN
  • Phone+81 662022161
  • Fax+81 662299596
  • Websitehttps://www.shionogi.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		4507:TYO since
announced		Transaction
value
Akros Pharma IncAnnounced07 May 202507 May 2025Announced3.72%24.00m
Japan Tobacco Inc-Pharmaceutical BusinessAnnounced07 May 202507 May 2025Announced3.72%37.90m
Data delayed at least 15 minutes, as of Jul 01 2025 07:30 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.